Literature DB >> 25381590

Reduced-dose cyclophosphamide in combination with fludarabine and anti-thymocyte globulin as a conditioning regimen for allogeneic hematopoietic stem cell transplantation for aplastic anemia.

Sumiko Kohashi1, Takehiko Mori, Risa Hashida, Jun Kato, Masuho Saburi, Taku Kikuchi, Yuya Koda, Takaaki Toyama, Yusuke Yamane, Satomi Yamanaka, Shinichiro Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25381590     DOI： 10.1007/s12185-014-1697-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  10 in total

1.  Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party.

Authors:  A Bacigalupo; F Locatelli; E Lanino; J Marsh; G Socié; S Maury; A Prete; A Locasciulli; S Cesaro; J Passweg
Journal:  Bone Marrow Transplant       Date:  2005-12       Impact factor: 5.483

2.  Guest editorial: advances in the management of acquired aplastic anemia.

Authors:  Shinji Nakao
Journal:  Int J Hematol       Date:  2013-04-21       Impact factor: 2.490

3.  Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.

Authors:  Ramaprasad Srinivasan; Yoshiyuki Takahashi; J Philip McCoy; Igor Espinoza-Delgado; Colleen Dorrance; Takehito Igarashi; Andreas Lundqvist; A John Barrett; Neal S Young; Nancy Geller; Richard W Childs
Journal:  Br J Haematol       Date:  2006-05       Impact factor: 6.998

4.  A combination of fludarabine, half-dose cyclophosphamide, and anti-thymocyte globulin is an effective conditioning regimen before allogeneic stem cell transplantation for aplastic anemia.

Authors:  Masahiro Ashizawa; Yu Akahoshi; Hirofumi Nakano; Tomotaka Ugai; Hidenori Wada; Ryoko Yamasaki; Yuko Ishihara; Koji Kawamura; Kana Sakamoto; Miki Sato; Kiriko Terasako; Shun-Ichi Kimura; Misato Kikuchi; Hideki Nakasone; Shinichi Kako; Junya Kanda; Rie Yamazaki; Aki Tanihara; Junji Nishida; Yoshinobu Kanda
Journal:  Int J Hematol       Date:  2014-02-01       Impact factor: 2.490

5.  Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.

Authors:  Igor B Resnick; Memet Aker; Michael Y Shapira; Panagiotis D Tsirigotis; Menachem Bitan; Ali Abdul-Hai; Simcha Samuel; Aliza Ackerstein; Benjamin Gesundheit; Irina Zilberman; Svetlana Miron; Luba Yoffe; Alex Lvovich; Shimon Slavin; Reuven Or
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

6.  Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.

Authors:  Andrea Bacigalupo; Gerard Socie'; Edoardo Lanino; Arcangelo Prete; Franco Locatelli; Anna Locasciulli; Simone Cesaro; Avichai Shimoni; Judith Marsh; Mats Brune; Maria Teresa Van Lint; Rosi Oneto; Jacob Passweg
Journal:  Haematologica       Date:  2010-05-21       Impact factor: 9.941

Review 7.  Cytomegalovirus infection/disease after hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato
Journal:  Int J Hematol       Date:  2010-04-23       Impact factor: 2.490

8.  In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.

Authors:  Yoshinobu Kanda; Kumi Oshima; Shinichi Kako; Takahiro Fukuda; Naoyuki Uchida; Koichi Miyamura; Yukio Kondo; Shinji Nakao; Koji Nagafuji; Toshihiro Miyamoto; Mineo Kurokawa; Yasushi Okoshi; Shigeru Chiba; Yasuo Ohashi; Yoichi Takaue; Shuichi Taniguchi
Journal:  Am J Hematol       Date:  2013-02-28       Impact factor: 10.047

9.  Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function.

Authors:  Shinya Okuda; Kiriko Terasako; Kumi Oshima; Miki Sato; Hideki Nakasone; Shinichi Kako; Rie Yamazaki; Yukie Tanaka; Aki Tanihara; Takakazu Higuchi; Junji Nishida; Yoshinobu Kanda
Journal:  Am J Hematol       Date:  2009-03       Impact factor: 10.047

Review 10.  Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.

Authors:  S Gandhi; A G Kulasekararaj; G J Mufti; J C W Marsh
Journal:  Int J Hematol       Date:  2013-04-30       Impact factor: 2.490
  10 in total
  1 in total

1.  Impact of cyclophosphamide dose of conditioning on the outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia from human leukocyte antigen-identical sibling.

Authors:  Takehiko Mori; Hideo Koh; Yasushi Onishi; Shinichi Kako; Makoto Onizuka; Heiwa Kanamori; Yukiyasu Ozawa; Chiaki Kato; Hiroatsu Iida; Ritsuro Suzuki; Tatsuo Ichinohe; Yoshinobu Kanda; Tetsuo Maeda; Shinji Nakao; Hirohito Yamazaki
Journal:  Int J Hematol       Date:  2016-02-24       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.